Liposome-loaded thermo-sensitive hydrogel for stabilization of SN-38 via intratumoral injection: optimization, characterization, and antitumor activity

References

• Bala V, Rao S, Boyd BJ, Prestidge CA. 2013. Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38. J Control Release. 172:48–61.
   PubMed Web of Science ®Google Scholar
• Bodurka DC, Levenback C, Wolf JK, Gano J, Wharton JT, Kavanagh JJ, Gershenson DM. 2003. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol. 21:291–297.
   PubMed Web of Science ®Google Scholar
• Burke TG, Mi Z. 1993. Ethyl substitution at the 7 position extends the half-life of 10-hydroxycamptothecin in the presence of human serum albumin. J Med Chem. 36:2580–2582.
   PubMed Web of Science ®Google Scholar
• Burke TG, Staubus AE, Mishra AK, Malak H. 1992. Liposomal stabilization of camptothecin's lactone ring. J Am Chem Soc. 114:117–120.
   Web of Science ®Google Scholar
• Casadó A, Giuffrida MC, Sagristá ML, Castelli F, Pujol M, Alsina MA, Mora M. 2016. Langmuir monolayers and Differential Scanning Calorimetry for the study of the interactions between camptothecin drugs and biomembrane models. Biochim Biophys Acta. 1858:422–433.
   PubMed Web of Science ®Google Scholar
• Cong W, Liu Q, Chen X, Gao R, Lu J, Wang Y, Luo G. 2010. Characterization and pharmacokinetics of a novel pirarubicin liposome powder. Drug Dev Ind Pharm. 36:1186–1194.
   PubMed Web of Science ®Google Scholar
• Dos Santos AC, Akkari AC, Ferreira IR, Maruyama CR, Pascoli M, Guilherme VA, de Paula E, Fraceto LF, de Lima R, Melo Pda S, et al. 2015. Poloxamer-based binary hydrogels for delivering tramadol hydrochloride: sol-gel transition studies, dissolution-release kinetics, in vitro toxicity, and pharmacological evaluation. Int J Nanomedicine. 2015:2391–2401.
   Google Scholar
• Du Y, Wei Z, He R, Ismail M, Ling L, Chen Y, Fu Z, Li X. 2017. Dual 7-ethyl-10-hydroxycamptothecin conjugated phospholipid prodrug assembled liposomes with in vitro anticancer effects. Bioorg Med Chem. 25:3247–3258.
   PubMed Web of Science ®Google Scholar
• Dumortier G, Grossiord JL, Agnely F, Chaumeil JC. 2006. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res. 23:2709–2728.
   PubMed Web of Science ®Google Scholar
• Ebrahimnejad P, Dinarvand R, Sajadi A, Jaafari MR, Nomani AR, Azizi E, Rad-Malekshahi M, Atyabi F. 2010. Preparation and in vitro evaluation of actively targetable nanoparticles for SN-38 delivery against HT-29 cell lines. Nanomedicine. 6:478–485.
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Supko JG. 2002. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res. 8:641–661.
   PubMed Web of Science ®Google Scholar
• Gaur PK, Mishra S, Gupta VB, Rathod MS, Purohit S, Savla BA. 2010. Targeted drug delivery of Rifampicin to the lungs: formulation, characterization, and stability studies of preformed aerosolized liposome and in situ formed aerosolized liposome. Drug Dev Ind Pharm. 36:638–646.
   PubMed Web of Science ®Google Scholar
• Hamidi M, Azadi A, Rafiei P. 2008. Hydrogel nanoparticles in drug delivery. Adv Drug Deliv Rev. 60:1638–1649.
   PubMed Web of Science ®Google Scholar
• Hua S, Wu SY. 2013. The use of lipid-based nanocarriers for targeted pain therapies. Front Pharmacol. 4:143–149.
   PubMed Web of Science ®Google Scholar
• Jeong B, Kim SW, Bae YH. 2002. Thermosensitive sol-gel reversible hydrogels. Adv Drug Deliv Rev. 54:37–51.
   PubMed Web of Science ®Google Scholar
• Kai M, Mino-Kenudson M, Sahani D, Holalkere NS, Fowers K, Rathi R, Brugge WR. 2007. EUS-guided injection of paclitaxel (OncoGel) provides therapeutic drug concentrations in the porcine pancreas. Gastrointest Endosc. 65:448–453.
   PubMed Web of Science ®Google Scholar
• Koning GA, Storm G. 2003. Targeted drug delivery systems for the intracellular delivery of macromolecular drugs. Drug Discov Today. 8:482–483.
   PubMed Web of Science ®Google Scholar
• Kweekel D, Guchelaar HJ, Gelderblom H. 2008. Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat Rev. 34:656–669.
   PubMed Web of Science ®Google Scholar
• Lavelle F, Bissery MC, André S, Roquet F, Riou JF. 1996. Preclinical evaluation of CPT-11 and its active metabolite SN-38. Semin Oncol. 23:11–20.
   PubMed Web of Science ®Google Scholar
• Lee ES, You HB. 2008. Recent progress in tumor pH targeting nanotechnology. J Control Release. 132:164–170.
   PubMed Web of Science ®Google Scholar
• Li J, Mooney DJ. 2016. Designing hydrogels for controlled drug delivery. Nat Rev Mater. 1:16071–16017.
   PubMed Web of Science ®Google Scholar
• Lin CC, Metters AT. 2006. Hydrogels in controlled release formulations: network design and mathematical modeling. Adv Drug Deliv Rev. 58:1379–1408.
   PubMed Web of Science ®Google Scholar
• Lin Z, Mei D, Chen X, Wang Y, Chen Y, Wang Z, He B, Zhang H, Wang X, Dai W, et al. 2015. A comparative study of thermo-sensitive hydrogels with water-insoluble paclitaxel in molecule, nanocrystal and microcrystal dispersions. Nanoscale. 7:14838–14847.
   PubMed Web of Science ®Google Scholar
• Lu XY, Hu S, Jin Y, Qiu LY. 2012. Application of liposome encapsulation technique to improve anti-carcinoma effect of resveratrol. Drug Dev Ind Pharm. 38:314–322.
   PubMed Web of Science ®Google Scholar
• Mourtas S, Haikou M, Theodoropoulou M, Tsakiroglou C, Antimisiaris SG. 2008. The effect of added liposomes on the rheological properties of a hydrogel: a systematic study. J Colloid Interface Sci. 317:611–619.
   PubMed Web of Science ®Google Scholar
• Nirmal HB, Bakliwal SR, Pawar SP. 2010. In-situ gel: new trends in controlled and sustained drug delivery system. Int J Pharm Res. 2:1398–1408.
   Google Scholar
• Oguma T. 2001. Antitumor drugs possessing topoisomerase I inhibition: applicable separation methods. J Chromatogr B Biomed Sci Appl. 764:49–58.
   PubMed Web of Science ®Google Scholar
• Ohtsuka K, Inoue S, Kameyama M, Kanetoshi A, Fujimoto T, Takaoka K, Araya Y, Shida A. 2003. Intracellular conversion of irinotecan to its active form, SN-38, by native carboxylesterase in human non-small cell lung cancer. Lung Cancer. 41:187–198.
   PubMed Web of Science ®Google Scholar
• Oussoren C, Storm G. 2001. Liposomes to target the lymphatics by subcutaneous administration. Adv Drug Deliv Rev. 50:143–156.
   PubMed Web of Science ®Google Scholar
• Peikov V, Ugwu S, Parmar M, Zhang A, Ahmad I. 2005. pH-dependent association of SN-38 with lipid bilayers of a novel liposomal formulation. Int J Pharmaceut. 299:92–99.
   PubMed Web of Science ®Google Scholar
• Ramesh M, Ahlawat P, Srinivas NR. 2010. Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 24:104–123.
   PubMed Web of Science ®Google Scholar
• Ren S, Dai Y, Li C, Qiu Z, Wang X, Tian F, Zhou S, Liu Q, Xing H, Lu Y, et al. 2016. Pharmacokinetics and pharmacodynamics evaluation of a thermosensitive chitosan based hydrogel containing liposomal doxorubicin. Eur J Pharm Sci. 92:137–145.
   PubMed Web of Science ®Google Scholar
• Roger E, Lagarce F, Benoit JP. 2011. Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration. Eur J Pharm Biopharm. 79:181–188.
   PubMed Web of Science ®Google Scholar
• Sapra P, Zhao H, Mehlig M, Malaby J, Kraft P, Longley C, Greenberger LM, Horak ID. 2008. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clin Cancer Res. 14:1888–1896.
   PubMed Web of Science ®Google Scholar
• Shikanov A, Shikanov S, Vaisman B, Golenser J, Domb AJ. 2011. Paclitaxel tumor biodistribution and efficacy after intratumoral injection of a biodegradable extended release implant. Int J Pharm. 358:114–120.
   Google Scholar
• Shoichet MS, Tator CH, Poon P, Kang C, Baumann MD. 2007. Intrathecal drug delivery strategy is safe and efficacious for localized delivery to the spinal cord. Prog Brain Res. 161:385–392.
   PubMed Web of Science ®Google Scholar
• Taich P, Moretton MA, Del Sole MJ, Winter U, Bernabeu E, Croxatto JO, Oppezzo J, Williams G, Chantada, LG, Diego A, et al. 2016. Sustained-release hydrogels of topotecan for retinoblastoma. Colloids Surfaces B. 146:624–631.
   PubMed Web of Science ®Google Scholar
• Thakur R, Sivakumar B, Savva M. 2010. Thermodynamic studies and loading of 7-ethyl-10-hydroxycamptothecin into mesoporous silica particles MCM-41 in strongly acidic solutions. J Phys Chem B. 114:5903–5911.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. 2005. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 4:145–160.
   PubMed Web of Science ®Google Scholar
• Ur-Rehman T, Tavelin S, Gröbner G. 2011. Chitosan in situ gelation for improved drug loading and retention in poloxamer 407 gels. Int J Pharm. 409:19–29.
   PubMed Web of Science ®Google Scholar
• Wang S, Ye T, Yang B, Yi X, Yao H. 2013. 7-Ethyl-10-hydroxycamptothecin proliposomes with a novel preparation method: optimized formulation, characterization and in vivo evaluation. Drug Dev Ind Pharm. 39:393–401.
   PubMed Web of Science ®Google Scholar
• Xu S, Wang W, Li X, Liu J, Dong A, Deng L. 2014. Sustained release of PTX-incorporated nanoparticles synergized by burst release of DOX⋅HCl from thermosensitive modified PEG/PCL hydrogel to improve anti-tumor efficiency. Eur J Pharm Sci. 62:267–273.
   PubMed Web of Science ®Google Scholar
• Ye T, Jiang X, Li J, Yang R, Mao Y, Li K, Li L, Chen F, Yao J, Wu Y, et al. 2015. Low molecular weight heparin mediating targeting of lymph node metastasis based on nanoliposome and enzyme-substrate interaction. Carbohydr Polym. 122:26–38.
   PubMed Web of Science ®Google Scholar
• Ye T, Xu W, Shi T, Yang R, Yang X, Wang S, Pan W. 2015. Targeted delivery of docetaxel to the metastatic lymph nodes: a comparison study between nanoliposomes and activated carbon nanoparticles. J Pharm Sci. 10:64–72.
   Web of Science ®Google Scholar
• Ye T, Zhang W, Sun M, Yang R, Song S, Mao Y, Yao J, Yang X, Wang S, et al. 2014. Study on intralymphatic-targeted hyaluronic acid-modified nanoliposome: influence of formulation factors on the lymphatic targeting. Int J Pharmaceut. 471:245–257.
   PubMed Web of Science ®Google Scholar
• Zhang JA, Xuan T, Parmar M, Ma L, Ugwu S, Ali S, Ahmad I. 2004. Development and characterization of a novel liposome-based formulation of SN-38. Int J Pharm. 270:93–107.
   PubMed Web of Science ®Google Scholar